Abstract
Up to now, evaluation of the immune status in tumor patients has been rather disappointing and has not shown clear-cut parameters that can be employed on a day-to-day basis to establish a prognosis, modify treatment, or allow early detection of relapse at the subclinical stage. Part or all these shortcomings can be explained by several findings. To begin with, tumor antigens in man remain poorly defined, making it impossible to precisely evaluate any specific immune response directed against this antigen. In addition, the immune mechanism governing rejection of human tumors remains poorly understood for the following reasons: The role of certain evaluations in vitro are not as evident within an in vivo context, e.g., T-cell cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), and natural killer (NK) cell activity; different lymphocyte subpopulations are still phenotypically and functionally poorly characterized; and, the role of immune complexes, inflammatory proteins, monocytes and macrophages, as well as leukocytes in antitumor response is still partially speculative.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Blomgren H, Einhorn S, Strander H (to be published) The influence of bestatin on the lymphoid system in the human. In: Umezawa H (ed) Small molecular immunomodulators.
Blomgren H, Einhorn S, Strander H (to be published) Modulation of the immune response by interferon in vivo and in vitro. In: Serrou B, Rosenfeld C (eds) New trends in human immunology and cancer immunotherapy. Doin-Saunders., Amsterdam New York
Bollag W (1979) Retinoids and cancer. Cancer Chemother Pharmacol 3:204–215
Bruley-Rosset M, Florentin I, Kiger N, Schulz G, Mathé G (1979) Restoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology 38:75–83
Caraux J, Goldstein AL, Esteve C, Serrou B (1979) Thymosin alpha-1 restores the depressed binding of autologous erythrocytes by T cells from cancer patients. Biomedicine 31:88
Caraux J, Thierry C, Esteve C, Flor es G, Lodise R, Serrou B (1979) Human autologous rosettes. I. Mechanism of binding of autologous erytrocytes by T cells. Cell Immunol 45:36–48
Caraux J, Thierry C, Serrou B (1979) Human autologous rosettes. II. Prognostic significance of variations in autologous rosette forming cells in the peripheral blood of cancer patients. J Natl Cancer Inst 63:593–597
Carpentier N, Lambert PH (to be published) Circulating immune complexes in human acute leukemia and lympho-proliferative disease relation to prognosis and study of the composition. In: Serrou B, Rosenfeld C (eds) New trends in human immunology and cancer immunotherapy. Doin-Saunders, Amsterdam, New York
Chretien PB, Lipson SD, Makuch R (1979) Effects of thymosin in vitro in cancer patients. Ann NY Acad Sci 332:135–147
Cupissol D, Moscati G, Rosenfeld C, Serrou B (1979) Plasma microviscosity in patients bearing solid tumors: Clinical and prognostic values. Med Oncol 55:14
Day NK, Witkin S, Good RA (to be published) Breast cancer: Circulating immune complexes and humoral antibodies to mouse mammary tumor virus. In: Serrou B, Rosenfeld C (eds) New trends in human immunology and Cancer immunotherapy. Doin-Saunders, Amsterdam, New York
Gallagher JG, Louie AC, Sikora K, Levy R, Rosenberg SA, Merigan TC (to be published) The evaluation of human leukocate interferon in patients with non-Hodgkin‘s lymphoma and Hodgkin’s disease: A phase II study. In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Gauci L, Caraux J, Serrou B (to be published) Immune complexes in the context of the immune response in cancer patients. In: Serrou B, Rosenfeld C (eds) Immune complexes and peasmapheresis in cancer patients. Human cancer immunology, vol 1. North-Holland Publishing, Amsterdam New York
Heiniger HJ, Brunner KT, Cerottini JC (1980) Cholesterol is a critical cellular composent for T-lymphocyte cytotoxicity. Proc Natl Acad Sci USA 75:5683–5687
Hogan-Ryan A, Fennelly JJ (1978) Neuraminidase-like effect of vitamin A on cell surface. Eur J Cancer 14:113–116
Krown S, Stoopler M, Gralla R, Cunningham-Rundles S, Stewart W, Pollack L, Oettgen H (to be published) Phase II trial of human leukocyte interferon (HuLelF) in non-small cell lung cancer (NSCLC). In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Mellstedt H, Aahre A, Bjorkholm M et al. (to be published) Interferon therapy of patients with myeloma. In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Petitou M, Tuy F, Rosenfeld C et al. (1978) Decreased microviscosity of membrane lipids in leukemic cells: Two possible mechanisms. Proc Natl Acad Sci USA 75:2306–2310
Phillips T, Lewis M, Neefe J, Smith F, Schein P, McDonald JS (to be published) Studies on the composition and significance of immune complexes in cancer patients. In: Serrou B, Rosenfeld C (eds) New trends in human immunology and cancer immunotherapy. Doin-Saunders, Amsterdam New York
Reinherz EL, Moretta L, Roper M, Breard JM, Mingari Cooper M, Schlossman SF (1980) Human T lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. J Exp Med 151:969–974
Rosenfeld C, Jasmin C, Mathé G, Inbar M (1979) Dynamic and composition of cellular membranes and serum lipids in malignant disorders. Recent Results Cancer Res 67:63–77
Serrou B, Cupissol D (to be published) Phase I evaluation of an aromatic derivative of retinoic acid (RO 109359) in patients with advanced solid tumors. Cancer Treat Rep
Serrou B, Rosenfeld C (to be published) New trends in human immunology and cancer immunotherapy. Doin-Saunders, Amsterdam New York
Serrou B, Rosenfeld C (to be published) Human suppressor cells in cancer patients. Human Cancer immunology, vol 2. North-Holland Publishing, Amsterdam New York
Serrou B, Cupissol D, Flad H et al. (to be published) Phase I evaluation of bestatin in patients bearing advanced solid tumors. In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York
Soukop H, Calmann CH (1978) Vitamin A status and chemotherapeutic response in cancer patients. In: Siegenthaler W, Luthy R (eds) Current chemotherapy. Proceedings of the Tenth International Congress of Chemotherapy, vol 2. American Society Microbiology, Washington, pp 1296–1298
Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, a new aminopeptidase B inhibitor produced by actinomycites. J Antibiot (Tokyo) 29:97–99
Wile AG, Sparks FC, Morton DL (1977) Monitoring immunotherapy with bacillus Calmette Guerin by antibody titer. Cancer Res 37:2251–2256
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Serrou, B., Cupissol, D., Rosenfeld, C. (1982). Immune Imbalance and Immune Modulation in Solid Tumor Patients: New Insights. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive